Precision BioSciences (DTIL) SEC Filings: History & Chart

Precision BioSciences, Inc.(DTIL)

Biotechnology · Durham, NC

$6.34+0.03 (+0.48%)

Delayed quote: Oct 6, 2026, 11:40 AM EDT

About Precision BioSciences, Inc.

Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.

Durham, NC

67 employees

www.precisionbiosciences.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Michael Amoroso

View full financials

Form	Filing Date	Accepted	Document
4	Sep 30, 2026	Sep 30, 2026	View filing
4	Sep 29, 2026	Sep 29, 2026	View filing
4	Sep 29, 2026	Sep 29, 2026	View filing
SC 13G/A	Aug 24, 2026	Aug 24, 2026	View filing
8-K	Aug 24, 2026	Aug 24, 2026	View filing
S-8	Aug 7, 2026	Aug 7, 2026	View filing
10-Q	Aug 6, 2026	Aug 6, 2026	View filing
8-K	Aug 6, 2026	Aug 6, 2026	View filing
3	Aug 3, 2026	Aug 3, 2026	View filing
3	Aug 3, 2026	Aug 3, 2026	View filing
3	Aug 3, 2026	Aug 3, 2026	View filing
SC 13G/A	Jul 29, 2026	Jul 29, 2026	View filing
8-K	Jul 27, 2026	Jul 27, 2026	View filing
SC 13G	Jul 20, 2026	Jul 20, 2026	View filing
8-K	Jul 1, 2026	Jul 1, 2026	View filing
8-K	Jun 16, 2026	Jun 16, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 5, 2026	Jun 5, 2026	View filing
4	Jun 3, 2026	Jun 3, 2026	View filing
4	Jun 3, 2026	Jun 3, 2026	View filing
4	Jun 3, 2026	Jun 3, 2026	View filing
4	Jun 3, 2026	Jun 3, 2026	View filing
8-K	May 27, 2026	May 27, 2026	View filing
8-K	May 26, 2026	May 26, 2026	View filing
4	May 22, 2026	May 22, 2026	View filing
4	May 22, 2026	May 22, 2026	View filing
4	May 22, 2026	May 22, 2026	View filing

SEC Filings

Recent Filings